Biochemist

JSC Biochemist operates in full compliance with GMP (Good Manufacturing Practice) standards.

History

2026: Obtaining GMP Certificate Opening the Pharmaceutical Market of Uzbekistan

The Biochemist plant was audited Ministries of Health of the Republic of Uzbekistan and confirmed compliance with strict international GMP standards. The certificate opens up the possibility of supplying the Company's medicines Promomed to one of the most dynamically developing pharmaceutical markets in Eurasia. Promomed announced this on February 18, 2026.

𝓲

Фото: Promomed

During the inspection, international experts praised the level of technical equipment, production lines, the pharmaceutical quality system and the high level of professionalism and competence of personnel. The company operates on the principle of full cycle. The presence of its own R&D-centre allows the Company to develop and implement innovative solutions from a molecule to a finished dosage form.

At the flagship production site of PROMOMED, modern endocrinological preparations are produced - Velgiya Eco and Tirzetta, which are planned to be supplied to the market of Uzbekistan. Preparations are created using modern technologies, without the use of preservatives such as benzyl alcohol and phenol. As part of the expansion of the product portfolio, the list of supplies also includes drugs for the treatment of cancer and modern highly effective means to combat infections.

The pharmaceutical market of Uzbekistan is one of the fastest growing in the region. At the end of 2025, according to IQVIA, its growth in monetary terms was about 23% and 5% in packages. At the same time, the best dynamics is shown by drugs against diabetes (with the exception of insulins) and drugs for the therapy of obesity, the average annual growth of which in the context of 2023-2025 was 57% in packages and 112% in monetary terms.

One of the key reasons for this rate is the prevalence of cardiovascular, endocrine and respiratory diseases. More than half (55%) of the pharmaceutical market in Uzbekistan is occupied by drugs for the therapy of chronic pathologies.

We expect that our interaction will allow us to close the needs of the Republic's health care system in critical areas, "said Alisher Zakirov, head of the PROMOMED Group representative office in Uzbekistan. - We set ourselves the task of providing both patients and the professional community with modern drugs that will bring to a new level the therapy of obesity and type 2 diabetes, cancer. In addition, we plan to supply drugs aimed at combating infections. Our task is to offer the health care system of Uzbekistan innovations focused on the long-term improvement of the quality of life of patients.

The export of Russian medicines is of particular importance in the context of international recognition of domestic pharmaceuticals. Obtaining a GMP certificate issued by a foreign regulator confirms the competitiveness of Russian industries and their compliance with international quality and safety standards.

A wide portfolio of the Company's products covering key therapeutic areas is planned for registration and circulation in the Republic of Uzbekistan. Collectively, the list may include more than 20 names in various dosage forms and dosages. Expanding the geography of supplies allows PROMOMED to increase the availability of pharmaceutical innovations regardless of borders and contribute to the development of international cooperation in the field of health.

2023

Opening of a plant for the production of active pharmaceutical substances for 3.7 billion rubles

On March 30, 2023, on the basis of Biochemist JSC, which is part of the Promomed group of companies, a plant for the production of active pharmaceutical substances (API), which is one of the largest in the country, was opened. This was reported to Zdrav.Expert on March 30, 2023 by representatives of Promomed. According to them, the production capacity is 340 tons per year for 150 types of substances. Investments in the project exceeded 3.7 billion rubles.

A plant for the production of substances for drugs for 3.7 billion rubles was opened in Russia
Photo: Promomed Group of Companies
Photo (from left to right): Head of the Republic of Mordovia Artyom Zdunov and Chairman of the Board of Directors of Promomed Group of Companies Pyotr Beliy

The opening ceremony was attended by the President of the Russian Federation Vladimir Putin and the Deputy Chairman, Governments Minister of Industry and Trade of the Russian Federation Denis Manturov in the regime, AEROSPACE FORCES the Head Republics of Mordovia Artyom Zdunov and Chairman of the Board of Directors of Promomed Group of Companies Pyotr Beliy.

The construction of the enterprise lasted 2 years. At the same time, most of the equipment was produced in Russia, emphasized in Promomed. In total, the plant combines seven sites, two of which will synthesize molecules for the manufacture of antitumor drugs. Other sites will produce molecules for synthetic antibiotics, with the exception of beta-lactam, antiviral and antiretroviral drugs, muscle relaxants.

According to the group of companies, the opening of the production complex will ensure the creation of more than 120 jobs, which is especially important for the region.

"The development of our own production of substances opens the way to obtaining more innovative molecules, which will make it possible to become more independent of imports and establish a full cycle of creating medicines within the country. To ensure the security of Russia in all its aspects, its own synthesis of substances is as important as space exploration, "said Pyotr Bely.

As of the beginning of 2022, the share of foreign substances was about 80% of the total volume on the Russian market. Of this volume, India and China supplied 76.7%, the EU countries - 19.7%, the rest of the countries - 3.6%.

Thanks to the opening of the plant, Promomed expects to increase the availability of effective and safe drugs for Russian citizens. The company plans to further expand the portfolio of drugs for the treatment of socially significant diseases and their production in a full cycle.

"We are opening the production of substances. But this is preceded by a lot of work on the development of drugs. Our manufacturers sometimes have to contact foreign laboratories. We want to ensure our full independence here. Therefore, we are working on the issue of creating a federal center in the republic, which will allow the development of medicines, "said Artyom Zdunov.

Investing 4.7 billion rubles in the production of drugs against cancer

Promomed Group of Companies initiates the construction of a workshop for the production of anticancer drugs in Saransk. The enterprise, in the creation of which 4.7 billion rubles will be invested, is planned to be located on the territory of the Biochemist plant. This was reported in March 2023 on the website of the Government of the Republic of Mordovia.

In addition to the construction of the workshop, the GC plans several more projects in Mordovia. This is, in particular, the launch of the production of active pharmaceutical substances with a capacity of 340 tons per year for 150 species. It is specified that the facility will become one of the largest factories for the production of pharmaceutical substances in Russia. 3.5 billion rubles will be invested in the implementation of the project.

First Deputy Minister of Industry and Trade of the Russian Federation Vasily Osmakov at the Biochemist plant

Also, the Promomed group announced its intention to commission a section for the production of medicines in the form of lyophilisates, the production capacity of which will be more than 4 million vials per year. Investments in this project are estimated at 1.2 billion rubles.

On March 10, 2023, First Deputy Minister of Industry and Trade of the Russian Federation Vasily Osmakov visited Biochemist. During the visit, new and under construction sites were inspected, including the production of pharmaceutical substances, which is planned to be opened in the spring of 2023, as well as the modern production of solid tablet forms with the possibility of vacuum transmission, commissioned in December 2022.

At the workshop held after the inspection of the enterprise, it was noted that over the past few years, Biochemist has made significant progress in the development of its scientific and production potential. At the same time, there are a number of promising innovative projects, to the implementation of which it is important to connect the scientific component and receive federal support.^[1]

2022

Opening of high-tech tablet production for 1.8 billion rubles

On December 17, 2022, on the basis of the Biochemist plant, the production site of the Promomed Group of Companies in Saransk, a high-tech tablet production was opened. This was reported to Zdrav.Expert by representatives of the Promomed Group of Companies.

The high-tech line of Biochemist JSC is intended for the production of strategically important drugs, including in case of cessation of supplies of foreign pharmaceutical companies, according to the instructions of the Ministry of Trade and Industry of the Russian Federation and the Ministry of Health of the Russian Federation. Production capacity is planned at the level of 1 billion tablets per year. Investments in the project amounted to more than 1.8 billion rubles.

В Mordovia launched high-tech production of strategically important drugs for 1.8 billion rubles

"The pharmaceutical industry responded to the challenges in a timely manner COVID-19 and quickly established the production of drugs that saved thousands of lives of our citizens. countries I would like to express confidence that the inclusion of a new production site in the cage of Russian pharmaceutical manufacturers will allow us to become more confident, this will be the key to the development of the general health care and pharmaceutical industry in particular, "said of the Russian Federation Mikhail Murashko the Minister of Health of the Russian Federation.

At the newly opened production, antiviral, non-steroidal anti-inflammatory, heparoprotective drugs will be produced, and in the near future the production of drugs in the form of sachets will be established. Control over ensuring the required conditions and process parameters is carried out using means of monitoring, data collection, dispatching and timely control of process parameters, which makes it possible to produce high quality products on all lines of the Biochemist plant, Promomed emphasized.

According to representatives of Promomed, the group's tablet production is one of the most modern production facilities in Europe, where vacuum transmission technologies are used instead of human labor. The line is equipped with technologies, including for the manufacture of multilayer and compound tablets produced in photosensitivity and zero humidity conditions.

"Now Russia has equipment for the production of modern drugs of any degree of complexity that save lives for the treatment of especially important nosologies," concluded Pyotr Beliy, Chairman of the Board of Directors of Promomed Group of Companies.

Receiving 2 billion rubles for the production of cancer drugs

On August 22, 2022, it became known about a loan of 2 billion rubles, which the Industrial Development Fund (FRP) provided to Biochemist for the production of cancer drugs. With this money, the Saransk Pharmaceutical Plant will launch three production lines for the production of drugs for the treatment of cancer.

The line includes 23 names, including antitumor drugs for chemotherapy and immunosuppressants. The medicinal products will be manufactured in the form of tablets and capsules, in the form of lyophilisates and solutions in vials, as well as in the form of pre-filled syringes.

Biochemist received 2 billion rubles for the production of cancer drugs

Such syringes have a number of advantages compared to traditional ones: speed and ease of use, accurate labeling and identification of the drug, reduced medical errors and contamination, an accurate predetermined dose and less overflow, TASS the press service of the FRP reports.

Every year, Biochemist expects to produce 26 million packages of cancer drugs. The oncological portfolio of the Promomed group, which includes Biochemist JSC, includes nine drugs for the treatment of cancer tumors by August 2022. These are, for example, Gemcitabine (for the therapy of tumors of the pancreas, lung cancer, bladder and breast cancer), Docetaxel (for the therapy of breast cancer, metastatic cancer of the prostate and stomach, malignant tumors of the head and neck), Sorafenib (for the therapy of myeloma).

The total costs of expanding the plant are estimated at 6.6 billion rubles. It is noted that the implementation of the project will create 172 jobs, including 159 high-performance ones.

FRP issued a loan to Biochemist under the Priority Projects program. The fund provides loans at 1% and 3% per annum for up to 10 years in the amount of 5 million to 5 billion rubles, stimulating the inflow of direct investments in the real sector of the economy.^[2]

2015: Joining the Promomed group

The Biochemist JSC plant became part of the Promomed group in 2015.

Notes